Archives
-
Monomethyl auristatin E (MMAE) Workflow Guide
2026-10-02
Build reproducible MMAE assays for payload benchmarking, antibody-drug conjugate development, and tumor-model studies. This guide connects tubulin-directed cytotoxicity with plasticity-focused readouts while separating established evidence from practical optimization recommendations.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Assays
2026-10-01
Protect DFCP1–ATGL complexes and lipid-droplet proteins during cell or tissue extraction with a water-soluble, broad-spectrum inhibitor mixture. This guide connects inhibitor selection, EDTA management, and cold-chain handling to starvation-driven lipolysis, Co-IP, Western blot, and imaging workflows.
-
BMS-345541: IKK-1/IKK-2 Inhibition Workflows
2026-10-01
Build reproducible NF-κB experiments with BMS-345541, from solvent handling and cytokine assays to endothelial angiogenesis models. The workflow connects pathway inhibition with practical controls for inflammation research, cancer research, and mechanistic vascular studies.
-
C34 and TLR4: A Translational Test of Inflammation
2026-09-30
C34 offers a selective way to test whether TLR4 is a causal driver of inflammation across macrophage, intestinal, and microglial models. By connecting product-level pharmacology with evidence from Taxus chinensis neuroinflammation research, this article outlines a more rigorous path from pathway observation to translational confidence.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-30
FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin reagent for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell and tissue samples. It is suited to immunofluorescence staining and flow cytometry carbohydrate profiling, but it should not be treated as a universal glycan probe or used outside validated carbohydrate-binding workflows.
-
Bone Transport and TGF-β1 Signaling in DFU Healing
2026-09-29
A 2026 rat study identifies TGF-β1/TGFBR1 signaling as a mechanistic link between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. Its multi-omic and tissue-level evidence supports pathway-focused follow-up while leaving important questions about inhibitor specificity, dosing, and translation to human wounds.
-
EGFP mRNA m1Ψ: From Signal to Tissue-Targeted Strategy
2026-09-29
A thought-leadership guide to using Cap 1 EGFP mRNA containing N1-methylpseudouridine as a mechanistic assay control for mRNA delivery, translation, and tissue-targeting decisions. The discussion connects reporter biology with a preclinical study of muscle-selective LNPs while distinguishing assay evidence from therapeutic claims.
-
Mechanistic qPCR for Translational CRC Research
2026-09-28
A mechanistic and strategic guide to using SYBR Green qPCR for validating apoptosis and chemosensitization signals in colorectal cancer research, with practical guidance for selecting and deploying HotStart™ 2X Green qPCR Master Mix.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-28
FITC-Concanavalin A (ConA) Conjugate provides a fluorescent readout for accessible α-D-glucose and α-D-mannose residues on cell surfaces and in tissue samples. Use it as a carbohydrate-binding probe in immunofluorescence or flow cytometry workflows, not as a general protein stain or a detector of non-carbohydrate targets.
-
WY-14643: A PPARα Lens on Lipid Homeostasis
2026-09-27
WY-14643 (Pirinixic Acid) offers researchers a pharmacological way to probe PPARα-linked lipid regulation, inflammation, and metabolic phenotypes. A recent PFHxS study shows why this pathway matters in environmental biology—and why careful controls are essential when translating receptor activation across models.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-26
FITC-Concanavalin A is a fluorescent lectin conjugate for visualizing accessible α-D-glucose- and α-D-mannose-containing structures on cells and tissue samples. Use it for carbohydrate-focused immunofluorescence staining or flow cytometry—not to detect non-carbohydrate targets—and optimize staining conditions for each sample.
-
Licoricidin in HCC: Growth, Metastasis, and PI3K/AKT
2026-09-25
A preclinical study reports that licoricidin suppresses hepatocellular carcinoma cell growth and metastatic behavior, with results associated with cell-cycle arrest, apoptosis, altered EMT markers, and reduced PI3K/AKT signaling. The findings connect in vitro assays with xenograft and metastasis models, but do not yet establish a direct molecular target or clinical efficacy.
-
Nilotinib and UV Stress: Separating Signaling
2026-09-25
Nilotinib (AMN-107) offers a defined way to interrogate BCR-ABL, KIT, and related kinase signaling in cancer models. This article connects that target-specific approach to new findings on UV-triggered ribotoxic stress—and explains how to distinguish pathway engagement from cell death without implying an unproven drug effect.
-
Ruxolitinib in JAK-STAT Bench Workflows
2026-09-24
Use Ruxolitinib (INCB018424) to probe JAK1/2-dependent signaling alongside, rather than in place of, studies of upstream innate immune activation. This workflow pairs pathway-specific phospho-readouts with cytokine and viability measurements, helping separate direct JAK-STAT effects from broader changes in inflammatory responses.
-
Adipose Netrin-1 in Metabolic Regulation
2026-09-24
This study examines how adipose Netrin-1 relates to adipose tissue biology and systemic metabolic regulation, combining mouse models, cell experiments, and analysis of human adipose tissue datasets.